• Journal of Nutrition and Health
• /
• 제22권3호
• /
• pp.167-174
• /
• 1989

Vitamin B-2와 Vitamin B-6 결핍이 hematologic profile에 미치는 영향을 in vivo 계에서 알고보고자 하였다. 흰쥐에게 Vitamin B-2 결핍(-B2)식이, Vitamin B-6결핍(-B6)식이, Vitamin B-2와 Vitamin B-6복합 결핍(-B2-B6) 식이 또는 통제 식이를 6주 동안 공급한 후 희생시켜 Hematocrit (Ht), Hemoglobin(Hb), 혈장철 (PI), Transferrin포화도 (TS), 간장철 (LI)를 비교하였다. 통제군에 비하여 -B2군에서는 PI, TS, LI가 유의하게 낮았으나 Ht와 Hb은 유의한 차이가 없으며, -B6군에서는 Ht와 Hb는 유의하게 낮았으나 LI는 유의하게 높았다. 통제군에 비하여 -B2-B6군에서는 Hb, PI, TS, LI가 -B2군과 -B6군의 중간수준이었으며 Ht는 낮은 수준을 나타냈다. 2주간의 보충식이 후에는 -B2군과 -B6군에서 모든 혈액지표와 LI가 개선된 것으로 나타났다. 본연구의 결과는 Vitamin B-2와 Vitamin B-6의 섭취가 영양적 빈혈군에서 혈액 지표를 개선시켜 빈혈의 예방또는 치료에 중요하다는 것을 시사한다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권5호
• /
• pp.2093-2098
• /
• 2015

In patients with multiple myeloma (MM), once-weekly intravenous injection or twice-weekly subcutaneous injection (SC) of bortezomib has been proven to offer non-inferior efficacy to standard twice-weekly intravenous administration, with an improved safety profile. However, whether once-weekly SC bortezomib can further reduce the incidence rate of peripheral neuropathy (PN) and not compromise the efficacy remains to be investigated. 25 patients of MM treated with once-weekly SC bortezomib were reviewed in this study. The median treatment cycles were 4 (range, 2-9 cycles). Complete response (CR) rate was 52%, ${\geq}$very good partial response (VGPR) rate was 72%, and ${\geq}$partial response (PR) rate was 84%. 1-year and 2-year PFS rate was 63.0% and 34.3%, respectively, and 2-year OS rate was 100%. Any grade of PN was reported in 9 patients (36.0%), with 7 patients (28.0%) had grade 1 PN, and 2 patients (8.0%) had grade 2 PN. No patients reported grade 3/4 PN in this cohort. In conclusion, once-weekly subcutaneous administration of bortezomib offers excellent efficacy with a further improved safety profile, especially with regard to PN. It needs to be validated in future prospective randomized trials.

• 한국영양학회:학술대회논문집
• /
• 한국영양학회 2003년도 연합학술대회
• /
• pp.251.1-251.1
• /
• 2003

• Clinical and Experimental Pediatrics
• /
• 제62권8호
• /
• pp.312-316
• /
• 2019

Purpose: The major side effects of treatment with oxcarbazepine (OXC) are skin rash and hyponatremia. Hematologic side effects are reported rarely. The aim of this study was to investigate the rate and types of the hematologic side effects of OXC. Methods: The medical records of 184 patients diagnosed with epilepsy or movement disorder and on OXC monotherapy, at the Department of Pediatrics of Inje University Sanggye Paik Hospital from July 2001 to July 2018, were retrospectively reviewed. Results: Of the 184 patients, 10 (5.4%) developed leukopenia in addition to pancytopenia and 2 (1.0%) developed pancytopenia. Leukopenia developed in 11 days to 14 years after OXC administration and was more frequent in males than in females (male vs. female, 9 vs. 1; Fisher exact test, P<0.05). Of the eight patients with leukopenia alone, 7 continued OXC treatment; 6 improved without intervention; 1 was lost to follow-up; and 1 received a reduced OXC dose, who improved after intervention. Pancytopenia developed within 2 months of initiation of OXC treatment. Both patients initially continued OXC. One improved within 1 month and continued treatment with OXC, but the other showed progression of the side effect, leading to the discontinuation of OXC and subsequent improvement within 1 month. There were no significant differences in the ages of the patients, OXC dose, and duration of OXC treatment between patients with and without these side effects of OXC (P>0.05, t-test). Conclusion: OXC-induced leukopenia is not rare and may result in pancytopenia. Patients being treated with OXC should be regularly monitored for abnormal complete blood count profiles.

• Archives of Pharmacal Research
• /
• 제14권1호
• /
• pp.73-77
• /
• 1991

The effects of pyridoxine (PN) on rifampicin (RMF) toxicity were investigated by both in vivo and in vitro methods. RMF (30 mg/kg) was injected intraperitoneally and PN(150 mg/kg) was administered orally to rats for 10 consecutive days. After treatment, clinical chemistry and hematologic profiles were measured. RMF and PN plus RMF did not show any adverse effects at this in vivo experimental condition. Thymidine incorporations of mice bone marrow cells were examined in vitro. RMF showed a decrease in thymidine uptake in a dose-dependent manner, but PN showed a reversal of the thymidine uptake suppression caused by RMF (p<0.01). On the other hand, PN showed a decrease in thymidine uptake at a high concentration level.

• Journal of Medicine and Life Science
• /
• 제17권3호
• /
• pp.103-106
• /
• 2020

Bone marrow failure, such as aplastic or myelophthisic anemia, can occur due to an underlying lymphoid malignancy and cause life-threatening events. A 58-year-old man diagnosed with angioimmunoblastic T-cell lymphoma had recently visited the emergency department because of an altered level of consciousness caused by acute severe anemia. The laboratory findings were strongly suggestive of bone marrow failure syndrome. Bone marrow examination was immediately performed and, subsequently, dexamethasone was initiated to control the underlying lymphoma. Intravenous immunoglobulin was also administered in combination due to combined immune hemolytic anemia and thrombocytopenia. Bone marrow examination revealed a packed marrow with marked fibrosis and lymphoma involvement. A diagnosis of secondary myelofibrosis related to the underlying lymphoma was made, and sequential combination chemotherapy was introduced despite the presence of severe anemia and thrombocytopenia. After combination chemotherapy, his hematologic profile and underlying lymphoma improved. Better understanding of various hematologic manifestations and knowledge of the rare condition of lymphoma are essential for appropriate diagnostic approaches and treatment.

• 대한지역사회영양학회지
• /
• 제2권3호
• /
• pp.327-337
• /
• 1997

The purpose of this study was to investigate the differences in anthropometric, hematologic, and lipidologic data between normocholesterolemia and hypercholesterolemia and influencing factors in hypercholesterolemia in middle-aged men in Kwang-ju. 179 middle-aged men were involved. Anthropometric data(body weight, height, body circumferences and skinfold thickness) and hematologic data(blood pressure, fasting blood glucose, albumin and hemoglobin) were measured. Bleed lipid profile(total cholesterol, tr- iglyceride, phospholipid, HDI-cholesterol, LDL-cholesterol and VLDL-cholesterol) were analyzed. To determined using questionnaire. The subjects were classified as hypercholesterolemic based on The Guideline for Korean Hyperlipidemia. body mass index, systolic blood pressure, waist and hip circumference, and triceps, subcostal, abdomen, subscapular and suprailliac skinfold thicknesses of the hypercholesterolemic group were significantly higher than in the normocholesterolemic group. The concentrat- ion of cholesterol, triglyceride, phospholipod. HDL-cholesterol, LDL-cholesterol and VLDL -cholesterol of the hypercholesterolemic group were significantly higher than normocholesterolemic group. The concentration of cholesterol has a significantly positive correlation with body mass index, diastolic blood pressure, waist circumference, waist/thigh ratio and skinfold thickness(triceps, subcostal, abdomen, and supraillic skin- fold thickness). The general tendency of socioeconomec status, frequencyu of meat intake, smoking amounts and duration and duration and drinking frequencies and amount were higher in the hypercholesteolemic group but not significant. In conclusion, hypercholesterolemia in middle-aged men was closely correlated with upper body fat obesity and most of them had an accompanied high triglyceride level tendency.

• Tuberculosis and Respiratory Diseases
• /
• 제71권3호
• /
• pp.210-215
• /
• 2011

Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become the standard of treatment for these diseases. Although the toxicity profile of imatinib is superior to that of interferon or other cytotoxic agents, some adverse events including edema, gastrointestinal toxicities and hematologic toxicities are commonly observed in the patients treated by imatinib. We present two cases of imatinib induced interstitial pneumonitis during the treatment of a chronic phase of CML.

• 대한약침학회지
• /
• 제21권2호
• /
• pp.76-81
• /
• 2018

Objective: This study compared the safety and efficacy of $Safacto^{(R)}$ versus $xyntha^{(R)}$ in patients with severe hemophilia A. Methods: Thirty-three male patients with severe hemophilia A were randomly divided into two groups. Seventeen patients received $Safacto^{(R)}$ and 16 patients received $Xyntha^{(R)}$ for four consecutive times. The dosage of FVIII was 40-50 IU/kg for each injection. Plasma level of FVIII activity was evaluated before every injection, 15 minutes after the injection and one month after the start of the trial. The rate of factor VIII activity, pain and joint motion were also assessed before and after the treatment. Results: Plasma level of FVIII clotting activity in $Safacto^{(R)}$ and $Xyntha^{(R)}$ were $1.96{\pm}0.5IU/dl$ and $1.63{\pm}0.5IU/dl$ and increased to $88.84{\pm}25.2IU/dl$ and $100.09{\pm}17.8IU/dl$, respectively (P<0.001). Pain score and range of motion improvement were $9.3{\pm}0.9$ and $8.7{\pm}0.1$ in $Safacto^{(R)}$ (P=0.17); and $9.4{\pm}0.8$ and $8.8{\pm}0.3$ in $Xyntha^{(R)}$ (P=0.35), respectively. No allergic or other unfavorable reactions was observed with either of the preparations. Conclusion: This study showed that $Safacto^{(R)}$ has a favorable efficacy and safety profile.

• The Korean Journal of Physiology and Pharmacology
• /
• 제20권1호
• /
• pp.63-67
• /
• 2016

Severe graft-versus-host disease (GVHD) is an often lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). The safety of clinical-grade mesenchymal stem cells (MSCs) has been validated, but mixed results have been obtained due to heterogeneity of the MSCs. In this phase I study, the safety of bone marrow-derived homogeneous clonal MSCs (cMSCs) isolated by a new subfractionation culturing method was evaluated. cMSCs were produced in a GMP facility and intravenously administered to patients who had refractory GVHD to standard treatment resulting after allogeneic HSCT for hematologic malignancies. After administration of a single dose ($1{\times}10^6cells/kg$), 11 patients were evaluated for cMSC treatment safety and efficacy. During the trial, nine patients had 85 total adverse events and the rate of serious adverse events was 27.3% (3/11 patients). The only one adverse drug reaction related to cMSC administration was grade 2 myalgia in one patient. Treatment response was observed in four patients: one with acute GVHD (partial response) and three with chronic GVHD. The other chronic patients maintained stable disease during the observation period. This study demonstrates single cMSC infusion to have an acceptable safety profile and promising efficacy, suggesting that we can proceed with the next stage of the clinical trial.